|
Synonyms: DOV 216,419 | DOV-216419 | EB-1020 | Simtriyo®
centanafadine is an approved drug
Compound class:
Synthetic organic
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Centanafadine (EB-1020) was progressed as a clinical candidate, for potential to treat generalized anxiety and attention-deficit hyperactivity disorder (ADHD) [5-6]. First approval was granted by the US FDA in July 2026, to treat ADHD [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06926829 | A Long-term Trial of EB-1020 in Adult Patients With ADHD | Phase 3 Interventional | Otsuka Pharmaceutical Co., Ltd. | ||
| NCT06973577 | P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 Interventional | Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
| NCT07086313 | A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Phase 2/Phase 3 Interventional | Otsuka Pharmaceutical Co., Ltd. | ||
| NCT07087327 | A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Phase 3 Interventional | Otsuka Pharmaceutical Co., Ltd. | ||
| NCT05428033 | A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) | Phase 3 Interventional | Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | |
| NCT05257265 | A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder | Phase 3 Interventional | Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | |